1. Home
  2. GMRS vs CERS Comparison

GMRS vs CERS Comparison

Compare GMRS & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GMRS

GMR Solutions Inc. Class A Common Stock

N/A

Current Price

$11.17

Market Cap

551.0M

ML Signal

N/A

Logo Cerus Corporation

CERS

Cerus Corporation

N/A

Current Price

$2.29

Market Cap

465.5M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
GMRS
CERS
Founded
2018
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Transportation Services
EDP Services
Sector
Consumer Discretionary
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
551.0M
465.5M
IPO Year
2026
1996

Fundamental Metrics

Financial Performance
Metric
GMRS
CERS
Price
$11.17
$2.29
Analyst Decision
Buy
Strong Buy
Analyst Count
8
4
Target Price
★ $18.63
$5.13
AVG Volume (30 Days)
726.6K
★ 1.7M
Earning Date
11-09-2026
11-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 27.27
EPS
N/A
★ N/A
Revenue
N/A
★ $51,326,000.00
Revenue This Year
$5.13
$20.82
Revenue Next Year
$5.57
$9.02
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 30.68
52 Week Low
$9.00
$1.38
52 Week High
$15.98
$3.47

Technical Indicators

Market Signals
Indicator
GMRS
CERS
Relative Strength Index (RSI) 55.70 42.76
Support Level $9.75 $2.07
Resistance Level $14.14 $3.12
Average True Range (ATR) 0.51 0.09
MACD 0.19 0.02
Stochastic Oscillator 74.45 43.24

Price Performance

Historical Comparison
GMRS
CERS

About GMRS GMR Solutions Inc. Class A Common Stock

GMR Solutions Inc is a holding company, along with its various subsidiaries, that delivers compassionate, quality medical care, meeting a patient's unplanned and planned care needs. The group provides emergent, non-emergent, disaster response, and event medical services across the healthcare ecosystem, serving local communities, health systems, payors, public health, and local, state, and federal agencies within the United States.

About CERS Cerus Corporation

Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety, and generates revenue from the same.

Share on Social Networks: